Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

VentriPoint Medical System receives CE Mark approval

VentriPoint Diagnostics Ltd. is pleased to announce that it has received approval to CE Mark its VentriPoint Medical System (VMS) which generates critical heart measurements from 2D ultrasounds in a rapid, accurate and inexpensive manner not currently available.

10 Dec 2009

Regulus Therapeutics to host educational webinar about microRNA biology

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.

10 Dec 2009

New health study reveals Ontario women less likely to receive cardiac care than men

Gender differences persist in the quality of cardiac care across Ontario, according to a health study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES).

10 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

National Heart Lung and Blood Institute of NIH awards Grand Opportunities grant to BMC

Boston Medical Center (BMC), today announced that it has been awarded a Grand Opportunities (GO) grant by the National Heart Lung and Blood Institute of the National Institutes of Health (NIH).

9 Dec 2009

New research shows increase risk of cardiovascular disease for people on low-carbohydrate high-fat diets

New scientific research has shown that low-carbohydrate high-fat diets, made popular by the likes of the Atkins diet, do not achieve more weight loss than low-fat high-carbohydrate diets. Worryingly, the research, lead by Dr Steven Hunter from the Royal Victoria Hospital, Belfast, also shows significantly increased risks of cardiovascular disease for people following low-carbohydrate high-fat diets

9 Dec 2009

BIOLASE Technology's Waterlase MD laser system receives FDA marketing clearance

BIOLASE Technology, Inc., the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Waterlase MD™ laser system for removal of subgingival calculi to prevent and treat periodontitis, the greatest cause of tooth loss for adults over 35 and a condition impacting more than half of Americans over the age of 55, as reported by the American Academy of Periodontology (AAP).

9 Dec 2009

Manuscript on KBR method to be published in American Journal of Cardiology

VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") is pleased to announce that the manuscript entitled, "Accuracy of Knowledge Based Reconstruction (KBR) for Measurement of Right Ventricular Volume and Function in Patients with Tetralogy of Fallot" has been accepted for publication in the American Journal of Cardiology.

9 Dec 2009

MEP HG and heart experts discuss EU achievements in combating cardiovascular disease

Members of the European Parliament Heart Group (MEP HG) meet today (9 December), in Brussels, with the Cardiology profession and representatives of national Heart Foundations to evaluate the achievements at EU level in combating Cardiovascular Disease (CVD), and to reveal the need for further action.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Baylor Jack and Jane Hamilton Heart and Vascular Hospital receives AACVPR Innovation Award

For their unique Return to Work Lab which focuses on individualized rehabilitation for younger, more active cardiac patients, the Cardiac Rehabilitation program at the Baylor Jack and Jane Hamilton Heart and Vascular Hospital was recently awarded the Innovation Award from the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR).

8 Dec 2009

QuantRx Biomedical launches its new flagship POC diagnostic reader device at MEDICA 2009

QuantRx® Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today the successful debut of its new flagship point-of-care (POC) diagnostic reader device, Q-Reader™, at MEDICA 2009 on November 18-21, 2009, in Düsseldorf, Germany.

8 Dec 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

Scientists attribute breast cancer decline to publicity surrounding WHI results

Between 2002 and 2003, American women experienced a 7 percent decline in breast cancer incidence, which scientists attribute to the publicity surrounding results of the Women's Health Initiative (WHI).

8 Dec 2009

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

BMI and waist circumference explain one half of all fatal and one quarter of all non-fatal cardiovascular disease in those overweight and obese in ten-year follow-up study

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Study suggests sustained health risks linked to adverse childhood experiences

Research from the Institute of Psychiatry at King's College London has found that negative experiences in childhood may alter not only mental health but also physical health, into middle age and beyond.

8 Dec 2009

Discovery presents a vital step towards efficient treatment of vascular injuries

Hyperglycemia starts a complex chain of events that damages blood vessels and cause cardiovascular disease. Scientists at Lund University Diabetes Centre (LUDC) have now been able to demonstrate why this happens, as well as how the destructive chain can be broken.

7 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

VentriPoint Medical System receives CE Mark approval

Regulus Therapeutics to host educational webinar about microRNA biology

New health study reveals Ontario women less likely to receive cardiac care than men

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

National Heart Lung and Blood Institute of NIH awards Grand Opportunities grant to BMC

New research shows increase risk of cardiovascular disease for people on low-carbohydrate high-fat diets

BIOLASE Technology's Waterlase MD laser system receives FDA marketing clearance

Manuscript on KBR method to be published in American Journal of Cardiology

MEP HG and heart experts discuss EU achievements in combating cardiovascular disease

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Baylor Jack and Jane Hamilton Heart and Vascular Hospital receives AACVPR Innovation Award

QuantRx Biomedical launches its new flagship POC diagnostic reader device at MEDICA 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Scientists attribute breast cancer decline to publicity surrounding WHI results

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

CAM314 randomized Phase 3 clinical trial results released

Study suggests sustained health risks linked to adverse childhood experiences

Discovery presents a vital step towards efficient treatment of vascular injuries

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in